

NANOMETRICS INC  
Form 8-K  
January 18, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

January 13, 2012

Date of Report (date of earliest event reported)

**Nanometrics Incorporated**

(Exact name of Registrant as specified in charter)

Edgar Filing: NANOMETRICS INC - Form 8-K

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(I. R. S. Employer  
Identification No.)

1550 Buckeye Drive, Milpitas, California 95035

(Address of principal executive offices, including ZIP Code)

Registrant's telephone number, including area code: (408) 545-6000

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On January 13, 2012, Nanometrics Incorporated ( Company ) and KLA-Tencor Corporation ( KLA-Tencor ) entered into an agreement to resolve all existing patent litigation between the parties, including litigation in Delaware and California. The Company and KLA-Tencor entered into a settlement and limited patent cross license agreement ( Agreement ), pursuant to which the Company will make a one-time payment of \$2.5 million to KLA-Tencor. The Agreement also includes cross-licenses of the patents that were subject to the litigation.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 17, 2012

NANOMETRICS INCORPORATED

/s/ Ronald W. Kisling  
Ronald W. Kisling

Chief Financial Officer